Vimian’s Interim Report for the second quarter of 2021

Regulatory press release
Aug 25 2021

Vimian’s Interim Report for the second quarter of 2021

Continued strong organic growth and strengthened market positions in Q2

Revenue increased by 229 per cent to EUR 39.4m (12.0), and organic revenue growth was 25 per cent
Adjusted EBITA amounted to EUR 12.2m (3.6), corresponding to an adjusted EBITA margin of 30.8 per cent (29.7)
Operating profit totalled EUR 1.6m (-1.6), including items affecting comparability of EUR -7.6m (-4.2)
Earnings per share before and after dilution totalled EUR -0.01 (-0.00)

“We report strong organic growth of 25 per cent in the second quarter, where all business areas demonstrate continued expansion. Our MedTech segment has seen accelerated growth following continued solid demand and successful commercial initiatives. Specialty Pharma also showed strong and accelerating underlying organic growth, above the average for Vimian Group in the quarter. The Diagnostics segment had a quarter to quarter variation due to an exceptional first quarter boosted by backorder filling and distributor re-stocking. Veterinary Services is starting to see positive momentum as Europe is slowly reopening”, says Dr. Fredrik Ullman, CEO of Vimian Group.

Adjusted EBITA increased to EUR 12.2m (3.6) in the quarter and the adjusted EBITA margin increased to 30.8 per cent, compared to 29.7 per cent in the quarter last year.

“Our medium-term target of 35 per cent EBITA margin will see variations between quarters near-term as we continue to invest where opportunities arise, to drive profitable long-term growth”, says Dr. Fredrik Ullman, CEO of Vimian Group.

A telephone and web conference will be organised for investors, analysts and media, today at 09.30 (CET). The conference will be held in English and include a question and answer session.

To attend the telephone conference:
SE: +46850558356
UK: +443333009266
US: +16467224956

To attend the web conference:
Link: https://tv.streamfabriken.com/vimian-group-q2-2021

Related presentation materials will be available at Vimian’s corporate website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 450 people and have a combined annual turnover of approximately EUR 140 million. For more information, please visit: www.vimian.com.